DTx Pharma Appoints Peter Condon as Chief Business Officer

SAN DIEGO--(BUSINESS WIRE)-- DTx Pharma, Inc. (DTx), a privately-held biotechnology company developing novel RNA-based therapeutics to treat the genetic drivers of disease, today announced the appointment of Peter Condon as Chief Business Officer. Mr. Condon will be key to the next stage of the company’s growth as it continues to advance its (Fatty Acid Ligand Conjugated OligoNucleotide) FALCON platform and pipeline of RNA therapeutics. He will be responsible for shaping DTx Pharma’s business development strategy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220628005260/en/

Peter Condon (Photo: Business Wire)

“Peter is a seasoned professional with experience across large pharmaceutical and smaller biotechnology companies. He has a very strong record of establishing collaborations that have captured meaningful value and is well placed to help us grow, moving us forward with our organizational strategy and goals to advance a pipeline of RNA therapeutics for rare diseases. We are delighted to have him joining the team and look forward to working together,” said Arthur T. Suckow, Co-Founder and Chief Executive Officer of DTx Pharma.

Mr. Condon joins DTx Pharma with more than 20 years of experience in business development, commercial planning, and operations. He has held positions as the Vice President and Head of Business Development at Gossamer Bio, and senior roles in business development and commercial planning at Calico Life Sciences, Alexion Pharmaceuticals, and Genentech. Mr. Condon was also responsible for several key corporate transactions across therapeutic areas, including rare diseases, inflammation, and oncology. In addition, he founded an independent consultancy last year where he advised emerging biotech companies on strategy, capital raising, and operations.

Mr. Condon received his BA from Harvard University and his MBA from The Wharton School of Business.

“I have been very impressed with the FALCON platform and its potential to deliver oligonucleotide therapies to target tissues beyond the liver and am thrilled to join the highly accomplished team at DTx Pharma. I look forward to working in close collaboration with my new colleagues as we strive to make a meaningful difference in the lives of patients suffering from genetic diseases,” said Mr. Condon.

About DTx Pharma

DTx Pharma, Inc. is a private clinical-stage biotechnology company tackling the challenges associated with treating genetic conditions by leveraging RNA-based therapeutics. The company’s proprietary delivery technology platform utilizes fatty acids as targeting ligands to enable the delivery of oligonucleotide therapies to tissues and cell types throughout the body. In preclinical studies, DTx has demonstrated cellular uptake and broad activity of oligonucleotides in the retina, muscle, heart, neurons, T cells, and other specialized cell types. To advance the FALCON platform toward and into clinical development, DTx has raised more than $100M in combined investment from several of the world’s leading healthcare investors including RA Capital Management and Access Biotechnology, pharmaceutical companies such as Eli Lilly and Company, the National Institute of Health (NIH), and research foundations such as the CMT Research Foundation (CMTRF). To learn more about DTx Pharma, please visit www.dtxpharma.com and follow DTx on LinkedIn and Twitter @DTxPharma.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220628005260/en/